Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Savara (SVRA) Depreciation and Depletion (2016 - 2018)

Savara (SVRA) reported Depreciation and Depletion of $139000.0 for Q4 2018, up 52.75% year-over-year from $91000.0 in Q4 2017, and up 9.45% on a QoQ basis from $127000.0 in Q3 2018.

Savara (SVRA) has 3 years of Depreciation and Depletion data on file, last reported at $139000.0 in Q4 2018.

  • Quarterly Depreciation and Depletion rose 52.75% year-over-year to $139000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $526000.0 (up 44.9% YoY) and the FY2021 annual result came in at $100000.0, down 66.67% from the prior year.
  • Depreciation and Depletion rose to $139000.0 in Q4 2018 per SVRA's latest filing, from $127000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $153000.0 in Q2 2018 and bottomed at $85000.0 in Q2 2016.
  • The 3-year median for Depreciation and Depletion is $91000.0 (2017), against an average of $104545.5.
  • The widest annual swing landed in 2017, when Depreciation and Depletion gained 1.11%; it then jumped 68.13% in 2018.
  • Tracing SVRA's Depreciation and Depletion over 3 years: stood at $90000.0 in 2016, then advanced by 1.11% to $91000.0 in 2017, then soared by 52.75% to $139000.0 in 2018.
  • Per Business Quant, the three latest SVRA Depreciation and Depletion figures stand at $139000.0 (Q4 2018), $127000.0 (Q3 2018), and $153000.0 (Q2 2018).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation and Depletion (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1,395.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Savara 1.30 Bn 1.30 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2018 139,000.00
Dec 31, 2018 139,000.00
Sep 30, 2018 127,000.00
Sep 30, 2018 127,000.00
Jun 30, 2018 153,000.00
Jun 30, 2018 153,000.00
Mar 31, 2018 107,000.00
Mar 31, 2018 107,000.00
Dec 31, 2017 91,000.00
Dec 31, 2017 91,000.00
Sep 30, 2017 91,000.00
Sep 30, 2017 91,000.00
Jun 30, 2017 91,000.00
Jun 30, 2017 91,000.00
Mar 31, 2017 90,000.00
Mar 31, 2017 90,000.00
Dec 31, 2016 90,000.00
Dec 31, 2016 90,000.00
Sep 30, 2016 86,000.00
Sep 30, 2016 86,000.00
Jun 30, 2016 85,000.00
Jun 30, 2016 85,000.00